These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 24305729)

  • 81. The Lidose hard capsule formulation of fenofibrate is suprabioavailable compared to the nanoparticle tablet formulation under high-fat fed conditions.
    Verbeeck RK; De Niet S; Lebrun S; Tremege M; Rennie TW; Coffiner M; Streel B; Cahay B
    J Pharm Pharm Sci; 2015; 18(1):61-7. PubMed ID: 25877442
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Food increases the bioavailability of isotretinoin.
    Colburn WA; Gibson DM; Wiens RE; Hanigan JJ
    J Clin Pharmacol; 1983; 23(11-12):534-9. PubMed ID: 6582073
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Systematic review of low-dose isotretinoin for treatment of acne vulgaris: Focus on indication, dosage, regimen, efficacy, safety, satisfaction, and follow up, based on clinical studies.
    Sadeghzadeh-Bazargan A; Ghassemi M; Goodarzi A; Roohaninasab M; Najar Nobari N; Behrangi E
    Dermatol Ther; 2021 Jan; 34(1):e14438. PubMed ID: 33085149
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Isotretinoin.
    Khalil NY; Darwish IA; Al-Qahtani AA
    Profiles Drug Subst Excip Relat Methodol; 2020; 45():119-157. PubMed ID: 32164966
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Comparative pharmacokinetic profiles of a novel isotretinoin formulation (isotretinoin-Lidose) and the innovator isotretinoin formulation: a randomized, 4-treatment, crossover study.
    Webster GF; Leyden JJ; Gross JA
    J Am Acad Dermatol; 2013 Nov; 69(5):762-767. PubMed ID: 23953888
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Comparative Pharmacokinetic Profiles of a Novel Low-dose Micronized-isotretinoin 32 mg Formulation and Lidose-isotretinoin 40 mg in Fed and Fasted Conditions: Two Open-label, Randomized, Crossover Studies in Healthy Adult Participants.
    Madan S; Kumar S; Segal J
    Acta Derm Venereol; 2020 Feb; 100(4):adv00049. PubMed ID: 31774544
    [TBL] [Abstract][Full Text] [Related]  

  • 87. ARTICLE: Advances in Oral Isotretinoin Therapy.
    Jones M; Armstrong AW; Baldwin H; Stein Gold L; Kircik LH
    J Drugs Dermatol; 2021 May; 20(5):s5-s11. PubMed ID: 33938693
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.
    Webster GF; Leyden JJ; Gross JA
    J Drugs Dermatol; 2014 Jun; 13(6):665-70. PubMed ID: 24918555
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Improving bioavailability with a novel isotretinoin formulation (isotretinoin-Lidose).
    Tan J; Knezevic S
    Skin Therapy Lett; 2013; 18(6):1-3. PubMed ID: 24305729
    [TBL] [Abstract][Full Text] [Related]  

  • 90. New Formulations of Isotretinoin for Acne Treatment: Expanded Options and Clinical Implications.
    Bellomo R; Brunner M; Tadjally E
    J Clin Aesthet Dermatol; 2021 Dec; 14(12 Suppl 1):S18-S23. PubMed ID: 35291260
    [TBL] [Abstract][Full Text] [Related]  

  • 91.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 92.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 93.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 94.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 95.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.